Pazopanib (PAZ) and Sunitinib (SUN), are two oral multikinase angiogenesis inhibitors which are prescribed frequently. However, the outcomes in real world of Turkish population have not extensively been studied.
Patients assessed retrospectively at two Turkish hospitals between 2006 and 2016.
Median age of patients was 60 (28-87) years and 70% of patients were male. ECOG performance score was 0 and 1 in 73% of patients. Twelve patients (15%) had non-clear cell carcinoma histology. Pathological characteristics, MSKCC risk groups, median follow up, response rates and survival are shown in Table. In the SUN group, the patients had more grade 3-4 adverse events (Table).Table:
885P Patient characteristics, responses to treatment, survival, and adverse events
|Sunitinib (n = 41)||Pazopanib (n = 38)||p value|
|MSKCC risk group||Favorable 31% Intermediate 56% Poor 12.5%||Favorable 31% Intermediate 47% Poor 21%||p = 0.66|
|T3-T4 stage||49%||47%||p = 0.38|
|Node positivity (%)||20%||8%||p = 0.10|
|Local recurrence (%)||20%||30%||p = 0.36|
|Median follow-up||18 months||13 months||p = 0.21|
|ORR||34%||37%||p = 0.96|
|DCR||78%||87%||p = 0.046|
|Progression||73% (n = 30)||50% (n = 19)||p = 0.08|
|Median PFS||8months||8months||p = 0.49|
|Median OS||22 months||21 months||p = 0.21|
|Fatigue, all grades||45%||74%||p = 0.48|
|Skin changes, all grades||44%||44%||p = 0.24|
|Anemia, all grades||35%||42%||p = 0.75|
|Grade 3-4 adverse events||59%||16%||p |
In our study, there was no difference in terms of survival between two agents. However, patients treated with SUN had more grade 3-4 adverse effects which prompted dose reduction and cessation.
Clinical trial identification
Legal entity responsible for the study
Individuals, Meltem Ekenel and Senem Karabulut
All authors have declared no conflicts of interest.